Vol. 1 No. 9 (2021)
Reimbursement Reviews

Encorafenib (Braftovi)

Published September 16, 2021

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses encorafenib (Braftovi), 75 mg capsules, orally.
  • Indication: In combination with cetuximab, for the treatment of patients with mCRC with a BRAF V600E mutation, as detected by a validated test, after prior therapy.